# Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Source: https://onco.cc/trials/nct05479994/  
OnCo record `nct05479994` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Sonrotoclax in non-Hodgkin lymphoma and chronic lymphocytic leukaemia, run by BeiGene, active and no longer recruiting.

## Summary

Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma is a phase 2 interventional study registered as NCT05479994 by BeiGene, with 100 participants enrolled, started 2022-10-25 and due to reach its primary completion in 2025-01-24. Interventions recorded: BGB-11417.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05479994
- Phase: 2
- Setting: A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of BCL2 Inhibitor BGB-11417 in Adult Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Sponsor: BeiGene
- Enrolled: 100

## Sources

- ClinicalTrials.gov NCT05479994: https://clinicaltrials.gov/study/NCT05479994

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [Sonrotoclax](https://onco.cc/drugs/sonrotoclax/)
- companies: [BeOne Medicines (formerly BeiGene)](https://onco.cc/companies/beone/)

---
JSON: https://onco.cc/api/v1/entities/nct05479994.json